GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Net Income From Continuing Operations

U2Bio Co (XKRX:221800) Net Income From Continuing Operations : ₩-368 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is U2Bio Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. U2Bio Co's net income from continuing operations for the three months ended in Jun. 2024 was ₩-26 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-368 Mil.

U2Bio Co Net Income From Continuing Operations Historical Data

The historical data trend for U2Bio Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U2Bio Co Net Income From Continuing Operations Chart

U2Bio Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only 105.89 -1,480.59 9,236.34 13,160.00 645.90

U2Bio Co Quarterly Data
Jun22 Mar23 Jun23 Mar24 Jun24
Net Income From Continuing Operations 1,302.55 305.37 930.66 -342.65 -25.66

U2Bio Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-368 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U2Bio Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:031860 XKRX:347740 XKRX:245620 XKRX:086040 XKRX:229000 XKRX:253840 XKRX:122310 XKRX:363250 XKRX:950200 XKRX:109820 TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
N/A
Address
Basement 1, 68 Gumaro Songpagu, Seoul, KOR
Website
http://www.u2bio.co.kr
U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.

U2Bio Co Headlines

No Headlines